EyeGate Pharma has added $2 million to its second round, bringing the total to $12 million. The Nexus Group provided the new funds. EyeGate is using iontophoresis technology to deliver therapeutics for ocular indications.
- check out the release on EyeGate's second round
EyeGate opens up U.S. operations. Report
New biotech arrival gains $10M in venture funds. Report